（文章来源：证券时报网） 数据宝统计，截至14:42，泓博医药成交额10.06亿元，创2025年2月18日以来新高。最新股价上涨 19.99%，换手率20.88%。上一交易日该股全天成交额为4.60亿元。（数据宝） ...

Core Viewpoint - The pharmaceutical sector is experiencing significant stock price increases, with notable gains in several companies, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Performance - Weikang Pharmaceutical has seen its stock price rise by over 15% [1]. - Frontline Bio and Shanghai Yizhong have both increased by over 10% [1]. - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical are also experiencing upward trends in their stock prices [1].

Core Viewpoint - The innovative drug sector experienced a significant rally, with notable stock price increases among various companies [1] Group 1: Company Performance - Weikang Pharmaceutical saw its stock price rise by over 18% [1] - Qianfang Bio and Shanghai Yizhong both increased by more than 10% [1] - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical also experienced upward movement in their stock prices [1]

Market Overview - The Shanghai Composite Index closed at 4089.45 points, above the annual line, with a slight increase of 0.09% [1] - The total trading volume of A-shares reached 17815.48 billion yuan [1] Stocks Breaking Annual Line - A total of 124 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Keta Power (300153) with a deviation rate of 11.05% and a daily increase of 12.50% [1] - Tianjian Technology (002977) with a deviation rate of 9.75% and a daily increase of 10.00% [1] - Hongbo Pharmaceutical (301230) with a deviation rate of 9.27% and a daily increase of 10.27% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Hongdu Aviation (600316) with a daily increase of 8.58% and a deviation rate of 8.08% [1] - Jiuliang Co. (300808) with a daily increase of 5.79% and a deviation rate of 5.21% [1] - Zhongcheng Technology (920207) with a daily increase of 22.67% and a deviation rate of 4.84% [1] Summary of Stocks with Smaller Deviation Rates - Stocks that have just crossed the annual line with smaller deviation rates include: - Dongfang Guoxin (东方国信) and Fuchun Environmental (富春环保) with minimal deviation rates [1] - The table lists various stocks along with their daily performance metrics, including turnover rates and latest prices [1]

Core Viewpoint - The innovative drug sector has experienced a strong rally since the beginning of 2026, driven by favorable policies, improving fundamentals, and a recovering capital market [1][4]. Group 1: Market Performance - The innovative drug concept sector in A-shares has seen a continuous rise, with multiple stocks, including Hainan Haiyao and Beibete-U, reaching their daily limit [1]. - Since the start of 2026, the innovative drug sector has recorded four consecutive days of gains, with over ten stocks rising more than 20% in four trading days, and Beibete-U's stock price has increased by nearly 70% [1][2]. Group 2: Policy and Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for urgently needed foreign drugs, encouraging simultaneous global research and application in China [3]. - In 2025, China approved 76 innovative drugs for market entry, surpassing the 48 approved in 2024, marking a historical high [3]. Group 3: Industry Drivers - The recent rally in the innovative drug sector is attributed to several factors, including the implementation of new national medical insurance drug lists, which support the sales and market promotion of innovative drugs [4]. - The sector is also benefiting from advancements in cutting-edge fields such as ADC and small nucleic acids, attracting capital interest [4]. Group 4: Investment Focus - The investment focus for 2026 is shifting towards overseas expansion and emerging technologies, with an emphasis on business development (BD) as a long-term trend for Chinese innovative drugs [5]. - Companies with rapid milestone achievements in BD are expected to attract more market attention and investment opportunities [5].

Group 1 - The Shanghai Composite Index is at 4083.28 points, slightly down by 0.06%, with a total trading volume of 1.267668 trillion yuan [1] - 100 A-shares have surpassed their annual line, with notable stocks including Keta Power, Tianjian Technology, and Hongbo Pharmaceutical, showing divergence rates of 12.69%, 9.75%, and 7.46% respectively [1] - Stocks with smaller divergence rates that have just crossed the annual line include Linhai Co., Qingdao Kingway, and Haier Biomedical [1] Group 2 - The top three stocks with the highest divergence rates from the annual line are Keta Power (14.17% increase), Tianjian Technology (10.00% increase), and Hongbo Pharmaceutical (8.44% increase) [1] - The trading turnover rates for these stocks are 13.20%, 23.67%, and 6.70% respectively, indicating significant trading activity [1] - Other stocks with notable performance include Akoli (7.08% increase) and Hengjin Technology (7.99% increase), with divergence rates of 5.90% and 4.62% respectively [1]

Group 1 - The A-share market continues to show strength in innovative drug concept stocks, with notable gains from companies such as Bibot-U nearing the daily limit and reaching a new high, and Yuandong Bio rising over 9% [1] - The National Medical Products Administration (NMPA) is set to support the "China debut" of innovative drugs, with plans to implement a data protection system for drug trials and establish exclusive market periods for pediatric and rare disease medications by 2026 [1] - The NMPA has announced further optimization of the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients [1] Group 2 - Notable stock performances include Bibot-U with a 19.95% increase, Yuandong Bio up 9.33%, and Hongbo Pharmaceutical rising 8.16%, among others [2] - The total market capitalization for Bibot-U is 22.3 billion, while Yuandong Bio stands at 11.5 billion, and Hongbo Pharmaceutical at 4.867 billion [2] - Year-to-date performance shows Bibot-U leading with a 70.89% increase, followed by Hongbo Pharmaceutical at 16.74% and Lai Mei Pharmaceutical at 7.59% [2]

证券日报网讯 1月7日，泓博医药发布2025年前三季度权益分派实施公告称，公司2025年前三季度权益 分派方案为每10股派1元（含税），股权登记日为2026年1月12日，除权除息日为2026年1月13日。 （编辑 任世碧） ...

证券代码：301230 证券简称：泓博医药 公告编号：2026-001 上海泓博智源医药股份有限公司 2025年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、2025 年 11 月 14 日，公司召开了 2025 年第三次临时股东会，会议审议并通过了《关 于公司 2025 年前三季度利润分配方案的议案》，具体方案如下：公司拟以实施利润分配 方案时股权登记日已发行总股本扣除回购股份数为基数，向全体股东每 10 股派发现金红 利 1 元（含税），送红股 0 股（含税），不以公积金转增股本。若以公司现有总股本 139,586,605 2 股扣除回购专用账户中已回购股份后 137,540,405 股为基数测算，共计派发现金股利约 13,754,040.50 元（含税）。若在本利润分配方案实施前公司总股本发生变动，公司将按照 分配比例不变的原则对分配总额进行调整。 2、自分配方案披露至实施期间，本公司股本总额未发生变化。因公司实施回购方案， 公司回购专用账户持有的 2,046,200 股不参与本次利润分配。 3、本次实施的分配 ...

证券日报网讯1月5日，泓博医药（301230）在互动平台回答投资者提问时表示，随着公司自研DiOrion 平台的迭代升级，公司会根据不同研发场景的需求，结合技术适配度与成本效益，动态优化智能化工具 合作伙伴的选择。未来，公司将以开放的合作态度，持续强化研发体系的先进性与竞争力，相关进展请 以公告为准。 ...